TerminatedNot applicableNCT02134717

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Studying Sarcoidosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kevin F. Gibson
Principal Investigator
Kevin F Gibson, MD
DorothyP. and Richard P. SImmons Center for Interstitial Lung Disease at the University of Pittsburgh
Intervention
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks(drug)
Enrollment
3 target
Eligibility
18-80 years · All sexes
Timeline
2014 – 2015

Study locations (1)

Collaborators

University of Pittsburgh

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02134717 on ClinicalTrials.gov

Other trials for Sarcoidosis

Additional recruiting or active studies for the same condition.

See all trials for Sarcoidosis →

← Back to all trials